Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater body weight loss and higher rates of prediabetes-to-normoglycemia conversion compared to GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and placebo in non-diabetic obese individuals.
If you have obesity or are overweight without diabetes, a once-weekly dual-acting injection (tirzepatide) can lead to significant weight loss (up to 21% in trials) and often reverses prediabetes. This is more effective than older GLP-1 drugs. It requires lifestyle changes alongside the medication.
Due to impressive BW loss in nondiabetic obese, who received tirzepatide, this agent will presumably affect T2DM risk and reversion of prediabetes. ... The SURMOUNT-1 trial ... showed that treatment with tirzepatide (5, 10, and 15 mg, OW SC) induced substantial and sustained BW loss (the mean percentage change in BW -15.0%, -19.5%, -20.9%, respectively). ... Furthermore, most of the prediabetes patients (95.3%) at baseline, treated with tirzepatide, had reverted to normoglycemia, when compared with 61.9% of patients treated with placebo.
Why this rating
Based on large-scale, randomized, double-blind phase 3 clinical trials (SURMOUNT-1, STEP-1, SCALE) with statistically significant results.
Source
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 2022
DOI 10.1177/10742484221146371
More from this paper
- GLP-1 receptor agonists (semaglutide, liraglutide, exenatide) significantly reduce body weight and improve glucose metabolism in non-diabetic obese individuals and those with prediabetes, often leading to normoglycemia.Strong
- GLP-1 receptor agonists improve cardiovascular risk factors (blood pressure, lipid profiles, endothelial function) and reduce cardiovascular events in patients with type 2 diabetes and obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →